B of A Securities Upgrades Esperion Therapeutics to Buy, Raises Price Target to $4
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Jason Zemansky upgraded Esperion Therapeutics (NASDAQ:ESPR) from Underperform to Buy and raised the price target from $1.25 to $4.
June 15, 2023 | 10:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics (NASDAQ:ESPR) has been upgraded from Underperform to Buy by B of A Securities analyst Jason Zemansky, with a raised price target of $4.
The upgrade from Underperform to Buy and the increase in price target from $1.25 to $4 by B of A Securities analyst Jason Zemansky indicates a positive outlook for Esperion Therapeutics. This news is likely to have a positive short-term impact on the stock price as it reflects increased confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100